Osteoporosis, Postmenopausal: all 337 studies
Page 4 of 4. Open to participants first (29), then studies with results posted, then the rest; newest registration first within each.
- Risedronate Sodium in Post Menopausal OsteoporosisCompletedNCT00453492Phase 4
- Pharmacokinetics and Pharmacodynamics Study of Oral Salmon Calcitonin in Healthy Postmenopausal WomenCompletedNCT00411125Phase 1
- Risedronate in the Prevention of Osteoporosis in Postmenopausal WomenCompletedNCT00402441Phase 4
- A Pilot Study of Bone Mineral Density in Postmenopausal Women After Treatment for Breast CancerCompletedNCT00399321
- FLEX - Long-term Extension of FIT (Fracture Intervention Trial)(0217-051)CompletedNCT00398931Phase 3
- A Study to Compare the Efficacy of Alendronate With and Without Calcium or Calcium Alone In the Treatment of Osteoporosis in Postmenopausal Women (0217-088)(COMPLETED)CompletedNCT00398606Phase 3
- Effects of Water and Food Intake on the Pharmacokinetics and Pharmacodynamics of Oral Salmon Calcitonin in Healthy Postmenopausal WomenCompletedNCT00395395Phase 1
- A Comparison Study With Alendronate and Raloxifene in Postmenopausal Women With Osteoporosis (0217-189)CompletedNCT00389740Phase 3
- Study Comparing Arzoxifene With Raloxifene in Women After Menopause With OsteoporosisCompletedNCT00383422Phase 3
- Study Comparing Bioequivalence of Two New Formulations of Premarin/MPA With Premarin/MPA Reference Formulation.CompletedNCT00381251Phase 1
- Risedronate 75mg Dosed on 2 Consecutive Days Monthly in the Treatment of Osteoporosis in Postmenopausal WomenCompletedNCT00358176Phase 3
- Risedronate In The Prevention Of Osteoporosis In Osteopenic Postmenopausal WomenCompletedNCT00353080Phase 3
- Risedronate in Postmenopausal Women With Low Bone DensityCompletedNCT00351091Phase 2
- Natto Supplementation to Prevent Loss of Bone Mass in Women Immediately After MenopauseCompletedNCT00290212Phase 2
- Impact of Oral Ibandronate 150 mg Monthly on Structural Properties of Bone in Postmenopausal Osteoporosis (SPIMOS-3D)CompletedNCT00271713Phase 4
- Teriparatide and Strontium Ranelate Head-To-Head Comparison TrialCompletedNCT00239629Phase 4
- Study Evaluating Bazedoxifene Dose-Response in Japanese Patients With Postmenopausal Osteoporosis.CompletedNCT00238745Phase 2
- 3-Week Parathyroid Hormone-related Protein (PTHrP) Dose Escalation Study in Post-Menopausal WomenCompletedNCT00222872Phase 1
- Fosamax Bone Loss Study: Alendronate to Prevent Bone LossCompletedNCT00221312
- 2-Year Therapy With Teriparatide vs 1-yr Therapy Followed by 1-Year of Raloxifene or Calcium/Vit D in Severe Postmenopausal OsteoporosisCompletedNCT00191425Phase 4
- A Study to Assess the Safety and Efficacy of 3 Doses of ALX1-11 (50, 75, and 100µg) in the Treatment of Postmenopausal OsteoporosisCompletedNCT00172107Phase 2
- TOP: Recombinant Human Parathyroid Hormone (ALX1-11) on Fracture Incidence in Women With Postmenopausal OsteoporosisCompletedNCT00172081Phase 3
- Influence of Alfacalcidol on Falls in Osteopenic/Osteoporotic Postmenopausal Women (ALFA Study)CompletedNCT00168909Phase 4
- Effects of Tibilone on Bone Density, Menopause Symptoms and Breast Density in Women After Prophylactic OophorectomyCompletedNCT00165204Phase 2
- OPTAMISE: Clinical Effectiveness of Teriparatide After Alendronate or Risedronate Therapy in Osteoporotic Postmenopausal WomenCompletedNCT00130403Phase 4
- Study of Investigational Drug in Osteoporosis (MK-0217-908)CompletedNCT00092053Phase 3
- A Study and 12 Month Extension to Evaluate Two Investigational Drugs in Postmenopausal Women With Osteoporosis (MK-0217-907)CompletedNCT00092040Phase 3
- A Study to Evaluate the Safety and Tolerability of MK0217 in Women (0217-219)CompletedNCT00092027Phase 3
- A Study to Evaluate and Compare Alendronate and Risedronate on Bone Mineral Density in Women With Postmenopausal Osteoporosis (MK-0217-211)CompletedNCT00092014Phase 3
- Effects of Arzoxifene on Bone Fractures and Incidence of Breast CancerCompletedNCT00088010Phase 3
- Effects of Arzoxifene on Bone Mass and the UterusCompletedNCT00085956Phase 3
- Effects of Teriparatide in Postmenopausal Women With OsteoporosisCompletedNCT00079924Phase 4
- Patient- and Physician-Based Osteoporosis EducationCompletedNCT00073190Phase 1
- Combined Use of Teriparatide and Raloxifene in Postmenopausal Women With OsteoporosisCompletedNCT00046137Phase 3
- Sequential Use of Teriparatide and Raloxifene HCl in the Treatment of Postmenopausal Women With OsteoporosisCompletedNCT00035256Phase 4
- Combination Osteogenic Therapy in Established OsteoporosisCompletedNCT00018447Phase 2
- Effects of Black Cohosh on Menopausal Hot FlashesCompletedNCT00010712Phase 2